We noticed that a low level of GATA3 and FOS mRNA predicted poor outcomes for patients with luminal A or B and basal-like subtype breast cancers, and high FOSL1 expression also predicted a poor outcome for patients with luminal A subtype breast cancers (Fig. S7A). This evidence concerns the gene FOS and breast cancer.